SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/15/19 Actinium Pharmaceuticals, Inc. 10-K 12/31/18 63:5.1M Edgar Agents LLC/FA |
Document/Exhibit Description Pages Size 1: 10-K Annual Report HTML 706K 2: EX-3.7 Certificate of Amendment to Actinium's Certificate HTML 17K of Incorporation 3: EX-10.37 Consulting Agreement, Dated December 21, 2018, HTML 63K Between Actinium Pharmaceuticals, Inc. and Nitya Ray 4: EX-10.38 Amended and Restated at Market Issuance Sales HTML 237K Agreement, Dated December 28, 2018, by and Among Actinium Pharmaceuticals, Inc. and B. Riley Fbr, Inc. and Jonestrading Institutional Services LLC 5: EX-10.39 Seventh Amendment to the 2013 Amended and Restated HTML 21K Stock Plan, as Amended 6: EX-23.1 Consent of Gbh CPAs, Pc. HTML 18K 7: EX-23.2 Consent of Marcum LLP. HTML 18K 8: EX-31.1 Certification -- §302 - SOA'02 HTML 25K 9: EX-31.2 Certification -- §302 - SOA'02 HTML 25K 10: EX-32.1 Certification -- §906 - SOA'02 HTML 19K 11: EX-32.2 Certification -- §906 - SOA'02 HTML 19K 18: R1 Document and Entity Information HTML 56K 19: R2 Consolidated Balance Sheets HTML 88K 20: R3 Consolidated Balance Sheets (Parenthetical) HTML 41K 21: R4 Consolidated Statements of Operations HTML 52K 22: R5 Consolidated Statement of Changes in Stockholders' HTML 72K Equity 23: R6 Consolidated Statements of Cash Flows HTML 93K 24: R7 Description of Business and Summary of Significant HTML 60K Accounting Policies 25: R8 Derivative Liabilities HTML 34K 26: R9 Prepaid Expenses and Other Current Assets HTML 24K 27: R10 Property and Equipment HTML 30K 28: R11 Commitments and Contingencies HTML 35K 29: R12 Equity HTML 79K 30: R13 Income Taxes HTML 43K 31: R14 Subsequent Event HTML 24K 32: R15 Description of Business and Summary of Significant HTML 105K Accounting Policies (Policies) 33: R16 Description of Business and Summary of Significant HTML 36K Accounting Policies (Tables) 34: R17 Derivative Liabilities (Tables) HTML 34K 35: R18 Prepaid Expenses and Other Current Assets (Tables) HTML 24K 36: R19 Property and Equipment (Tables) HTML 29K 37: R20 Commitments and Contingencies (Tables) HTML 23K 38: R21 Equity (Tables) HTML 48K 39: R22 Income Taxes (Tables) HTML 40K 40: R23 Description of Business and Summary of Significant HTML 27K Accounting Policies (Details) 41: R24 Description of Business and Summary of Significant HTML 23K Accounting Policies (Details 1) 42: R25 Description of Business and Summary of Significant HTML 33K Accounting Policies (Details 2) 43: R26 Description of Business and Summary of Significant HTML 53K Accounting Policies (Details Textual) 44: R27 Derivative Liabilities (Details) HTML 25K 45: R28 Derivative Liabilities (Details 1) HTML 40K 46: R29 Derivative Liabilities (Details Textual) HTML 33K 47: R30 Prepaid Expenses and Other Current Assets HTML 30K (Details) 48: R31 Prepaid Expenses and Other Current Assets (Details HTML 21K Textual) 49: R32 Property and Equipment (Details) HTML 39K 50: R33 Property and Equipment (Details 1) HTML 24K 51: R34 Property and Equipment (Details Textual) HTML 23K 52: R35 Commitments and Contingencies (Details) HTML 33K 53: R36 Commitments and Contingencies (Details Textual) HTML 68K 54: R37 Equity (Details) HTML 66K 55: R38 Equity (Details 1) HTML 69K 56: R39 Equity (Details Textual) HTML 360K 57: R40 Income Taxes (Details) HTML 35K 58: R41 Income Taxes (Details 1) HTML 75K 59: R42 Income Taxes (Details Textual) HTML 42K 60: R43 Subsequent Event (Details) HTML 47K 62: XML IDEA XML File -- Filing Summary XML 102K 61: EXCEL IDEA Workbook of Financial Reports XLSX 60K 12: EX-101.INS XBRL Instance -- atnm-20181231 XML 1.01M 14: EX-101.CAL XBRL Calculations -- atnm-20181231_cal XML 103K 15: EX-101.DEF XBRL Definitions -- atnm-20181231_def XML 479K 16: EX-101.LAB XBRL Labels -- atnm-20181231_lab XML 835K 17: EX-101.PRE XBRL Presentations -- atnm-20181231_pre XML 674K 13: EX-101.SCH XBRL Schema -- atnm-20181231 XSD 134K 63: ZIP XBRL Zipped Folder -- 0001213900-19-004269-xbrl Zip 107K
Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO 18U.S.C SECTION 1350 AS ADOPTED
PURSUANT TO SECTION 302 OF THE SARBANES-OXELY ACT OF 2002
I, Sandesh Seth, certify that:
1. | I have reviewed this report on Form 10-K of Actinium Pharmaceuticals, Inc. for the fiscal year ended December 31, 2018. |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have: |
a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
5. | The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
Dated: March 15, 2019 | By: | /s/ Sandesh Seth |
Sandesh Seth | ||
Chairman
and Chief Executive Officer (Duly Authorized Officer, Principal Executive Officer) | ||
This ‘10-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 3/15/19 | None on these Dates | ||
For Period end: | 12/31/18 | |||
List all Filings |